Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab observational study in NMOSD with coexisting autoimmune diseases
ChiCTR2400090925Phase 4Recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), Sjögren's syndrome, systemic lupus erythematosus (SLE) and 3 more, sponsored by Shenzhen Second People's Hospital. Primary endpoint: Annual recurrence rate of NMOSD. Started Oct 2024; status: recruiting.
02
Drugs
inebilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)Sjögren's syndromesystemic lupus erythematosus (SLE)Undifferentiated Connective Tissue Disease (UCTD)Hashimoto's disease
Beyond the preview
Go deeper on ChiCTR2400090925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090925.